Managing Liver Health and Nutrition
At a Glance
Children with Aagenaes syndrome may need individualized medium-chain triglyceride nutrition, specialized vitamins, treatment for itching, and regular liver tests. Many remain stable, but ongoing monitoring helps detect poor nutrition or rare liver progression early and guides specialist care.
The liver component of Aagenaes syndrome (LCS1) is often most intense during infancy. While the “neonatal cholestasis” phase frequently improves as a child grows, the liver still requires specialized, lifelong management to ensure your child remains healthy and well-nourished [1][2].
Proactive Nutritional Support
When bile doesn’t flow correctly from the liver (cholestasis), the body struggles to absorb fats and fat-soluble vitamins. This can lead to malnutrition and growth delays if not managed proactively [3].
- MCT-Rich Feeding: Your child’s care team may recommend formulas or diets high in medium-chain triglycerides (MCTs). Unlike most fats, MCTs do not require as much bile to be absorbed, providing an efficient energy source for your baby [4]. However, MCTs must be individualized to prevent essential fatty acid deficiency, so a pediatric dietitian is a vital member of your team [5].
- The “ADEK” Vitamins: Because vitamins A, D, E, and K are fat-soluble, they often bypass the body in children with cholestasis. Deficiency can lead to issues with vision, bone strength, and blood clotting [6].
- Monitoring: Doctors will regularly check blood levels of these vitamins and your child’s INR (which can be abnormal because of vitamin K deficiency or impaired hepatic synthetic function) [6][7]. Albumin and vitamin levels also require clinical interpretation.
- Supplementation: Your child will likely need “water-miscible” or specialized vitamin preparations that improve absorption for a cholestatic liver [8]. High-dose vitamins A and D can be toxic, so doses and formulations must be prescribed and adjusted by the hepatology/dietitian team.
Managing Itching (Pruritus)
The buildup of bile salts in the blood can cause intense, sometimes debilitating itching (pruritus). There is no universal sequence for treating itch in Aagenaes syndrome; cholestyramine, rifampicin, opioid antagonists, sertraline, and IBAT inhibitors are selected according to the cause, age, drug interactions, local approvals, and specialist judgment:
- Ursodeoxycholic acid (UDCA): May be used for cholestatic liver disease, though it is not a universal first-line treatment specifically for cholestatic itch [9].
- Targeted Options: Rifampicin or cholestyramine are among the options a specialist might prescribe to target itching [10][11].
- Specialist Interventions: IBAT inhibitors are not established or routinely approved specifically for Aagenaes syndrome, and biliary-diversion surgery is not a standard escalation pathway for this condition [12][13]. Approvals and off-label use vary.
Long-Term Liver Monitoring
In Aagenaes syndrome, liver function often stabilizes after the first few years of life. A nine-year study of adults with the condition found that many remained stable with no clinical deterioration [2].
However, “stable” does not mean “normal.” Children typically have abnormal markers:
- GGT (Gamma-glutamyl transferase) and Alkaline Phosphatase (ALP): GGT can support assessment of cholestasis, but ALP is strongly age-dependent and is often physiologically high from bone growth; neither test alone measures liver function [2].
- Bile Acids: These often remain elevated even when the child looks healthy [2].
- Results must use pediatric reference ranges and be interpreted with bilirubin, transaminases, bile acids, albumin, INR, growth, examination, and other testing.
Understanding the Prognosis
Prognosis data is limited due to the rarity of the syndrome. However, many reported patients achieve stable liver disease and reach adulthood [2]. Some children experience episodic cholestasis, where liver symptoms (like jaundice) flare up during illness or pregnancy later in life [1].
In a small number of cases, the liver damage can progress to cirrhosis (scarring) or liver failure. While rare, parents should be aware that liver transplantation is considered for demonstrable progressive liver disease or complications, rather than as a routine baseline step [14][13]. Ongoing monitoring of “synthetic function” (the liver’s ability to make proteins like albumin) helps catch changes early [2].
Common questions in this guide
What nutrition support may a child with Aagenaes syndrome need?
Why does my child need vitamins A, D, E, and K for cholestasis?
What treatments can help itching in Aagenaes syndrome?
Which liver tests should be followed over time in Aagenaes syndrome?
What is the long-term outlook for children with Aagenaes syndrome?
When would liver transplantation be considered for Aagenaes syndrome?
Get notified when new evidence is published on Cholestasis-lymphedema syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Angioid streaks in aagenaes syndrome.
Shoumnalieva-Ivanova V, Tanev I, Zdravkov Y, et al.
International ophthalmology 2017; (37(4)):1065-1068 doi:10.1007/s10792-016-0344-y.
PMID: 27614462 - 2
A nine year follow-up study of patients with lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome).
Drivdal M, Holven KB, Retterstøl K, et al.
Scandinavian journal of clinical and laboratory investigation 2018; (78(7-8)):566-574 doi:10.1080/00365513.2018.1519723.
PMID: 30755100 - 3
Malnutrition in Pediatric Chronic Cholestatic Disease: An Up-to-Date Overview.
Tessitore M, Sorrentino E, Schiano Di Cola G, et al.
Nutrients 2021; (13(8)) doi:10.3390/nu13082785.
PMID: 34444944 - 4
Nutrition support of children with chronic liver disease: A rapid review and consensus statements from Australasian society of parenteral and enteral nutrition (AuSPEN) Paediatric liver group.
Burgess D, Collins T, Landorf E, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2026; (58(7)):862-870 doi:10.1016/j.dld.2026.05.006.
PMID: 42225462 - 5
Medium-chain triglycerides and the impact on fat absorption, growth, nutritional status and clinical outcomes in children with cholestatic liver disease: A scoping review.
Mancell S, Manwani K, Dhawan A, Whelan K
Clinical nutrition (Edinburgh, Scotland) 2023; (42(11)):2159-2172 doi:10.1016/j.clnu.2023.09.010.
PMID: 37776587 - 6
Fat Soluble Vitamin Assessment and Supplementation in Cholestasis.
Kamath BM, Alonso EM, Heubi JE, et al.
Clinics in liver disease 2022; (26(3)):537-553 doi:10.1016/j.cld.2022.03.011.
PMID: 35868689 - 7
Fat-soluble vitamin assessment, deficiency and supplementation in infants with cholestasis.
Mancell S, Islam M, Dhawan A, Whelan K
Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 2022; (35(2)):273-279 doi:10.1111/jhn.12957.
PMID: 34679231 - 8
Effect of medium chain triglycerides enriched formula on growth of biliary atresia patients after Kasai portoenterostomy.
El-Koofy N, Mahmoud E, El Mougy F, et al.
Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology 2024; (25(2)):188-193 doi:10.1016/j.ajg.2024.01.015.
PMID: 38378358 - 9
Efficacy and safety of ursodeoxycholic acid in children with cholestasis: A systematic review and meta-analysis.
Huang L, Li S, Chen J, et al.
PloS one 2023; (18(1)):e0280691 doi:10.1371/journal.pone.0280691.
PMID: 36719881 - 10
An update on the physiopathology and therapeutic management of cholestatic pruritus in children.
Thébaut A, Debray D, Gonzales E
Clinics and research in hepatology and gastroenterology 2018; (42(2)):103-109 doi:10.1016/j.clinre.2017.08.007.
PMID: 29031874 - 11
Cholestatic Pruritus in Children: Conventional Therapies and Beyond.
Rodrigo M, Dong X, Chien D, Karnsakul W
Biology 2023; (12(5)) doi:10.3390/biology12050756.
PMID: 37237568 - 12
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
Thompson RJ, Arnell H, Artan R, et al.
The lancet. Gastroenterology & hepatology 2022; (7(9)):830-842 doi:10.1016/S2468-1253(22)00093-0.
PMID: 35780807 - 13
Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis.
McKiernan P, Bernabeu JQ, Girard M, et al.
JHEP reports : innovation in hepatology 2024; (6(1)):100949 doi:10.1016/j.jhepr.2023.100949.
PMID: 38192535 - 14
A New Unc45a 5'utr Variant In Patients With Aagenaes Syndrome.
Tan TT, Dogan YC, Yilmaz ZB, et al.
American journal of medical genetics. Part A 2025; (197(6)):e64004 doi:10.1002/ajmg.a.64004.
PMID: 39887522
This page is for informational purposes only and does not constitute medical advice about your child’s Aagenaes syndrome. A pediatric hepatology team and dietitian should tailor supplements, medicines, laboratory monitoring, and transplant decisions to your child.